Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
US11820822B2 · kind B2 · utility
0Cited by
33References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 5, 2018 |
| Grant date | Nov 21, 2023 |
| Priority date | — |
| Expiry date | Jun 5, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is based, in part, on the identification of biomarkers, and methods of modulate thereof, for sensitizing cancer cells to T cell-mediated killing. For example, the present invention, in part, comprises methods of sensitizing cancer cells in a subject afflicted with a cancer to cytotoxic T cell-mediated killing comprising administering to a subject a therapeutically effective amount of an agent that modulates the biomarker.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.